FDA approves Lilly's Mounjaro to cut cardiovascular event risk in high-risk type 2 diabetes adults
LLY•Trial results
Mounjaro met non-inferiority, showing an 8% lower MACE-3 rate; hazard ratio 0.92 with 95.3% CI 0.83-1.01.
FDA approves Mounjaro label expansion
The FDA cleared Lilly’s Mounjaro to cut major cardiovascular event risk in adults with type 2 diabetes at high risk.
The label expansion follows SURPASS-CVOT, a 13,299-patient trial comparing tirzepatide with Trulicity over a median 210.1 weeks.
